Barclays
TXMD icon

Barclays’s TherapeuticsMD TXMD Stock Holding History

Barclays’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,040
Closed -$1.26M – 7401
2018
Q2 		$1.26M Buy
+4,040
New +$1.23M ﹤0.01% 3033

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Barclays's TXMD Position: Q2 2026 in Review

Barclays opened a new position in TherapeuticsMD (TXMD) in Q2 2026: 22 shares worth $49. The stake represents ﹤0.01% of the portfolio and ranks #5242 among its holdings. This is a return to the name: Barclays previously reported a position in TXMD as recently as Q3 2025.

Barclays first reported a position in TXMD in Q2 2013 and has held it in 36 quarters since. The position peaked at $698K in Q4 2015. 44 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

  • Barclays held 22 shares of TherapeuticsMD worth $49 as of Q2 2026.
  • TherapeuticsMD was a new Barclays position in Q2 2026.
  • TherapeuticsMD made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5242 holding.
  • Barclays first reported a position in TherapeuticsMD in Q2 2013 and has held it in 36 quarters since.
  • Barclays's TherapeuticsMD position peaked at $698K in Q4 2015.
  • 44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.